Dopaminergic stabilisers constitute a new class of CNS-active compounds able to both enhance and inhibit dopaminergic effects in the brain depending on the base level of dopamine activity. Dopamine is an important neurotransmitter in the brain, and the dopaminergic system plays a key role in the regulation of motor function and behaviour. Dopaminergic stabilisers are thus able to stabilise motor and behaviour disturbances caused by neurological and psychiatric disorders. These effects on diseases do not involve any adverse effect on the normal processes in the brain.
The drug discovery programme for dopaminergic stabilisers has already produced development candidates ACR16, ACR325 and ACR343. NSD-847 is the latest deliverable and has compared to the other three compounds an adjusted pharmacological profile and certain other features have been further improved.
